Expanding Access to Daily Oral PrEP for HIV Prevention in Underserved Communities of Rio de Janeiro Using Community and Digital Support

What this Trial Is About

This research aims to improve access to HIV prevention by increasing the use of pre-exposure prophylaxis PrEP among underserved groups in Rio de Janeiro, including gay and bisexual men, transgender women, and sex workers. It focuses on populations at higher risk who face obstacles to accessing and continuing PrEP, especially those living in socially and economically vulnerable communities. The study evaluates whether delivering PrEP through community-based settings can enhance uptake and continued use. Participants will receive HIV prevention services in non-traditional community settings such as non-governmental organizations and mobile health units. Daily oral PrEP with tenofovir disoproxil fumarateemtricitabine will be offered to those who test HIV-negative, alongside counseling and follow-up support. Telehealth consultations and mobile health mHealth tools will also be used to support adherence and retention. Those who test positive for HIV will be referred to appropriate treatment within the public health system. During the study, participants will undergo HIV testing, counseling, and clinical monitoring. Data will be collected through questionnaires and clinical assessments to evaluate PrEP uptake, adherence, retention, and HIV incidence over up to 12 months. Follow-up focus groups will provide insights into participants experiences with community-based PrEP delivery. The study will monitor the feasibility and acceptability of this approach and assess engagement with digital support tools.

Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro